AP929A - Sulfonyl urea derivatives. - Google Patents

Sulfonyl urea derivatives. Download PDF

Info

Publication number
AP929A
AP929A APAP/P/1998/001190A AP9801190A AP929A AP 929 A AP929 A AP 929A AP 9801190 A AP9801190 A AP 9801190A AP 929 A AP929 A AP 929A
Authority
AP
ARIPO
Prior art keywords
alkyl
hydrogen
hydroxy
urea
halo
Prior art date
Application number
APAP/P/1998/001190A
Other languages
English (en)
Other versions
AP9801190A0 (en
Inventor
Mark Anthony Dombroski
James Fredrick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9801190A0 publication Critical patent/AP9801190A0/xx
Application granted granted Critical
Publication of AP929A publication Critical patent/AP929A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
APAP/P/1998/001190A 1997-01-29 1998-01-29 Sulfonyl urea derivatives. AP929A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29

Publications (2)

Publication Number Publication Date
AP9801190A0 AP9801190A0 (en) 1998-03-31
AP929A true AP929A (en) 2001-01-18

Family

ID=21891776

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001190A AP929A (en) 1997-01-29 1998-01-29 Sulfonyl urea derivatives.

Country Status (40)

Country Link
US (2) US6166064A (fr)
EP (1) EP0964849B1 (fr)
JP (1) JP3573757B2 (fr)
KR (1) KR100324058B1 (fr)
CN (1) CN1127479C (fr)
AP (1) AP929A (fr)
AR (1) AR011093A1 (fr)
AT (2) ATE270285T1 (fr)
AU (1) AU723895B2 (fr)
BG (1) BG103597A (fr)
BR (1) BR9714328A (fr)
CA (1) CA2279186C (fr)
CO (1) CO4920230A1 (fr)
CZ (1) CZ293173B6 (fr)
DE (2) DE69722663T2 (fr)
DK (2) DK1270565T3 (fr)
DZ (1) DZ2407A1 (fr)
EA (1) EA001803B1 (fr)
ES (2) ES2222426T3 (fr)
HR (1) HRP980045B1 (fr)
HU (1) HUP0000567A3 (fr)
ID (1) ID22223A (fr)
IL (1) IL130855A0 (fr)
IS (1) IS5099A (fr)
MA (1) MA26468A1 (fr)
NO (1) NO313279B1 (fr)
NZ (1) NZ336248A (fr)
OA (1) OA11079A (fr)
PA (1) PA8444701A1 (fr)
PE (1) PE57898A1 (fr)
PL (1) PL335052A1 (fr)
PT (2) PT964849E (fr)
SK (1) SK283679B6 (fr)
TN (1) TNSN98017A1 (fr)
TR (1) TR199901816T2 (fr)
TW (1) TW515788B (fr)
UY (1) UY24861A1 (fr)
WO (1) WO1998032733A1 (fr)
YU (1) YU33799A (fr)
ZA (1) ZA98685B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (fr) * 1998-08-31 2005-11-16 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
WO2001019390A1 (fr) * 1999-09-14 2001-03-22 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (fr) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
US6780859B2 (en) 2001-09-14 2004-08-24 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
EP1487457A1 (fr) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combinaison d'un inhibiteur d'il-1/18 avec un inhibiteur de tnf pour le traitement d'inflammations
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
RU2236677C2 (ru) * 2002-06-24 2004-09-20 Чичкова Марина Александровна Способ прогнозирования раннего клинического течения экссудативного перикардита у больных с системными заболеваниями
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2004031777A1 (fr) * 2002-10-03 2004-04-15 Pfizer Products Inc. Utilisation de gst-omega-2 en tant que cible therapeutique
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
PL1776336T3 (pl) * 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
WO2006090932A1 (fr) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. Marqueur de substitution pour compose de sulfonamide
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP3180312B1 (fr) 2014-08-12 2019-10-16 Loyola University Of Chicago Inhibiteurs indoline-sulfonamide de dape et ndm-1 et utilisation de ceux-ci
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
US10688077B2 (en) * 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
CN109071454B (zh) 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
ES2940611T3 (es) * 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (fr) * 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
EP3548480A1 (fr) * 2016-11-29 2019-10-09 Epizyme, Inc. Composés contenant un groupe sulfonique en tant qu'inhibiteurs de kat
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951B8 (fr) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Nouveaux composés de sulfoximine substitués
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
EP3697758B1 (fr) 2017-10-17 2022-07-06 Novartis AG Sulfonamides et compositions associées pour le traitement d'états pathologiques associés à une activité de nlrp
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
EP3759077A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759078A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
SG11202012159TA (en) * 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
EP3823974A1 (fr) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN120208846A (zh) 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物
CN114641466B (zh) 2019-06-12 2025-09-30 诺瑟拉有限公司 磺酰脲衍生物及其用途
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021048809A1 (fr) * 2019-09-12 2021-03-18 Cadila Healthcare Limited Nouveaux dérivés de type sulfoximine substitués
US12428391B2 (en) 2020-06-11 2025-09-30 Cisen Pharmaceutical Co., Ltd Dimethylsulfoximine derivative
MX2022014709A (es) 2020-06-19 2022-12-16 Ac Immune Sa Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
WO2022022646A1 (fr) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 Composé cyclique hétéroaromatique à cinq chaînons contenant du sélénium
CN116783184A (zh) 2020-09-04 2023-09-19 诺瑟拉有限公司 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
CN118355000A (zh) * 2021-12-03 2024-07-16 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2023222565A1 (fr) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CA3261365A1 (fr) 2022-07-28 2024-02-01 Ac Immune Sa Nouveaux composés
WO2025133307A1 (fr) 2023-12-22 2025-06-26 Ac Immune Sa Modulateurs hétérocycliques de la voie de l'inflammasome nlrp3
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1
WO2025153624A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025153625A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025163069A1 (fr) 2024-01-31 2025-08-07 Ac Immune Sa Nouveaux composés
WO2025251275A1 (fr) * 2024-06-07 2025-12-11 上海麦克林生化科技股份有限公司 Procédé de préparation d'un nouveau composé benzylsulfinylpyridine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001684A1 (fr) * 1990-07-24 1992-02-06 Pfizer Inc. Derives de 3-(1-pyrazoyle substitue)-2-oxindole
WO1993008161A1 (fr) * 1991-10-15 1993-04-29 Warner-Lambert Company INHIBITEURS D'ACAT (ACYLE-CoA:CHOLESTEROL ACYLTRANSFERASE) A BASE DE CARBAMATES ET D'UREES SULFONYLE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001684A1 (fr) * 1990-07-24 1992-02-06 Pfizer Inc. Derives de 3-(1-pyrazoyle substitue)-2-oxindole
WO1993008161A1 (fr) * 1991-10-15 1993-04-29 Warner-Lambert Company INHIBITEURS D'ACAT (ACYLE-CoA:CHOLESTEROL ACYLTRANSFERASE) A BASE DE CARBAMATES ET D'UREES SULFONYLE

Also Published As

Publication number Publication date
CN1245490A (zh) 2000-02-23
CZ293173B6 (cs) 2004-02-18
ES2198598T3 (es) 2004-02-01
CZ257599A3 (cs) 2000-09-13
KR20000070541A (ko) 2000-11-25
SK283679B6 (sk) 2003-11-04
CA2279186C (fr) 2004-02-24
HUP0000567A2 (hu) 2000-10-28
TNSN98017A1 (fr) 2005-03-15
DK1270565T3 (da) 2004-10-04
CN1127479C (zh) 2003-11-12
MA26468A1 (fr) 2004-12-20
DZ2407A1 (fr) 2003-01-04
WO1998032733A1 (fr) 1998-07-30
PT964849E (pt) 2003-08-29
ZA98685B (en) 1999-07-29
OA11079A (en) 2002-03-14
ATE270285T1 (de) 2004-07-15
DE69722663T2 (de) 2004-04-29
IS5099A (is) 1999-06-29
PL335052A1 (en) 2000-03-27
AU723895B2 (en) 2000-09-07
IL130855A0 (en) 2001-01-28
NZ336248A (en) 2000-10-27
US6433009B1 (en) 2002-08-13
AP9801190A0 (en) 1998-03-31
HRP980045B1 (en) 2002-10-31
AU5234098A (en) 1998-08-18
HRP980045A2 (en) 1999-06-30
ATE242208T1 (de) 2003-06-15
KR100324058B1 (ko) 2002-02-16
NO313279B1 (no) 2002-09-09
SK98299A3 (en) 2001-10-08
EP0964849A1 (fr) 1999-12-22
DE69729762D1 (de) 2004-08-05
CO4920230A1 (es) 2000-05-29
NO993658D0 (no) 1999-07-28
TR199901816T2 (xx) 1999-11-22
ID22223A (id) 1999-09-16
PE57898A1 (es) 1999-06-11
PA8444701A1 (es) 2000-05-24
JP3573757B2 (ja) 2004-10-06
ES2222426T3 (es) 2005-02-01
DE69722663D1 (de) 2003-07-10
PT1270565E (pt) 2004-09-30
AR011093A1 (es) 2000-08-02
EP0964849B1 (fr) 2003-06-04
BR9714328A (pt) 2000-03-21
HUP0000567A3 (en) 2002-10-28
TW515788B (en) 2003-01-01
US6166064A (en) 2000-12-26
EA199900603A1 (ru) 2000-02-28
YU33799A (sh) 2002-03-18
UY24861A1 (es) 2000-09-29
CA2279186A1 (fr) 1998-07-30
JP2000511200A (ja) 2000-08-29
DK0964849T3 (da) 2003-08-25
BG103597A (bg) 2000-02-29
DE69729762T2 (de) 2005-07-14
NO993658L (no) 1999-09-28
EA001803B1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
AP929A (en) Sulfonyl urea derivatives.
EP1214087A1 (fr) Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
RU2321394C2 (ru) Замещенные фенилсульфонамидные ингибиторы продуцирования бета-амилоида
WO1998034915A1 (fr) Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
EA005210B1 (ru) Сульфонамиды гидроксидифенилмочевины в качестве антагонистов рецептора ил-8
US7563822B2 (en) Agents for the prevention or treatment of renal diseases
HU210057B (en) Process for the preparation of acetamide derivatives and pharmaceutical compositions containing the same
EP1270565A1 (fr) Furane-2-sulfonamide 4-substituée et son emploi dans la préparation de dérivés de sulfonylurée
MXPA99007030A (en) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US7022689B2 (en) 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor
EP1466899A1 (fr) Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active
HK1055945A1 (zh) 環已基(烷基)-丙醇胺及其製備方法和含有它們的藥物組合物
HK1055945B (en) Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same